Heidelberg Pharma AG (LTS:0QW5) Retained Earnings: €-376.82 Mil (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0QW5 Heidelberg Pharma AG LTS:0QW5
52 GF Score
Price €2.51
GF Value €3.07
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Heidelberg Pharma AG Retained Earnings?

Heidelberg Pharma AG LTS:0QW5 -0.40% 52 Retained Earnings is €-376.82 Mil as of May. 2026. GuruFocus rates LTS:0QW5 with a GF Score™ of 52/100 and a GF Value™ of €3.07 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Heidelberg Pharma AG's retained earnings for the quarter that ended in May. 2026 was €-376.82 Mil.

Heidelberg Pharma AG's quarterly retained earnings declined from Nov. 2025 (€-373.40 Mil) to Feb. 2026 (€-377.68 Mil) but then increased from Feb. 2026 (€-377.68 Mil) to May. 2026 (€-376.82 Mil).

Heidelberg Pharma AG's annual retained earnings declined from Nov. 2023 (€-311.74 Mil) to Nov. 2024 (€-331.12 Mil) and declined from Nov. 2024 (€-331.12 Mil) to Nov. 2025 (€-373.40 Mil).


Heidelberg Pharma AG  (LTS:0QW5) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Heidelberg Pharma AG Retained Earnings Historical Data

* Premium members only.

The historical data trend for Heidelberg Pharma AG's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Heidelberg Pharma AG Retained Earnings Chart

Heidelberg Pharma AG Annual Data
Trend Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23 Nov24 Nov25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -271.69 -291.39 -311.74 -331.12 -373.40

Heidelberg Pharma AG Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -343.71 -352.18 -373.40 -377.68 -376.82
LTS:0QW5
52GF Score
Heidelberg Pharma AG LTS:0QW5
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Heidelberg Pharma AG Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of €-376.82 Mil mean?
Heidelberg Pharma AG (LTS:0QW5) has a Retained Earnings of €-376.82 Mil as of May. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Heidelberg Pharma AG and its competitors.
Is Heidelberg Pharma AG's Retained Earnings too high?
Heidelberg Pharma AG's current Retained Earnings is €-376.82 Mil. Overall, Heidelberg Pharma AG has a GF Score™ of 52/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Heidelberg Pharma AG's Retained Earnings compare to VRTX and REGN?
Heidelberg Pharma AG's Retained Earnings of €-376.82 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Heidelberg Pharma AG and its competitors. Heidelberg Pharma AG's current Retained Earnings is €-376.82 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Heidelberg Pharma AG stock overvalued right now?
Based on GuruFocus' analysis, Heidelberg Pharma AG (LTS:0QW5) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.07, compared to a current price of €2.51 — trading 18.2% below its estimated fair value. The current Retained Earnings is €-376.82 Mil. Heidelberg Pharma AG's overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Heidelberg Pharma AG (LTS:0QW5), the current Retained Earnings is €-376.82 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Heidelberg Pharma AG (LTS:0QW5) Overvalued in 2026?

Based on GuruFocus' analysis, Heidelberg Pharma AG stock appears to be undervalued. The current stock price of €2.51 is trading 18.2% below its estimated GF Value™ of €3.07. GuruFocus considers Heidelberg Pharma AG to be Modestly Undervalued.

Key valuation signals for LTS:0QW5:

  • Retained Earnings: €-376.82 Mil
  • GF Value™: €3.07 vs. price of €2.51 (18.2% below fair value)
  • GF Score™: 52/100 with 5 warning signs

No single metric tells the full story. See the LTS:0QW5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Heidelberg Pharma AG Business Description

Other Exchanges HPHA:GermanyHPHA:Austria
Address Gregor-Mendel-Street 22, Ladenburg, DEU, 68526
Heidelberg Pharma AG is a biopharmaceutical company developing oncology treatments through antibody drug conjugates (ADCs), which combine antibody specificity with toxin potency to selectively target and kill cancer cells. The Company researches, develops, and produces these ADCs, and has built an ADC toolbox using various antibodies and payloads to address multiple cancers and overcome tumor resistance. Its activities focus on its proprietary ATAC technology based on Amanitin, the toxin of the death cap mushroom, leveraging its biological mechanism as a novel cancer therapy. The ATAC platform is used to develop proprietary ADC candidates and is also applied in collaborations with third parties.
52GF Score

Get the complete analysis for LTS:0QW5

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.51
Price
€3.07
GF Value